ARTICLE | Clinical News

Tracon reports Phase Ib data for carotuximab in NSCLC

December 8, 2017 6:57 PM UTC

In October, Tracon Pharmaceuticals Inc. (NASDAQ:TCON) reported data from 8 evaluable patients with stage IV non-squamous non-small cell lung cancer (NSCLC) in a Phase Ib trial showing that carotuximab (IV TRC105) in combination with paclitaxel/carboplatin and Avastin bevacizumab led to partial responses in 37% of patients, including 1 patient who had an 81% reduction in tumor volume. The combination led to median progression-free survival (PFS), a secondary endpoint, of 6.54 months.

No dose-limiting toxicities were observed. Data were presented at the International Association for the Study of Lung Cancer (IASLC) meeting in Yokohama...

BCIQ Company Profiles

Tracon Pharmaceuticals Inc.

BCIQ Target Profiles

Endoglin (CD105) (ENG)